BIOX Bioceres Crop Solutions Corp. IFRS
Agricultural Chemicals · Nasdaq · SEC CIK 1769484 · Fiscal year ends 06/30
Financial factors as of 2025-12-31 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-28.4%
TTM net income YoY-16,023.8%
TTM EPS YoY-9,660.3%
Revenue 3-yr CAGR-10.3%
Net income 3-yr CAGR—
Margins
Gross margin39.1%
Operating margin0.8%
Net margin-83.4%
FCF margin27.7%
EBITDA margin—
Returns
ROE-123.8%
ROA-34.2%
ROIC (approx.)0.5%
Asset turnover0.41x
Leverage & solvency
Liabilities / assets81.0%
Debt / equity1.63x
Current ratio0.90x
Interest coverage0.07x
Cash quality & payout
Operating cash flow / net income-0.34x
Accruals ratio-46.0%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 | FY20212021-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $335.11M | $464.78M | $420.06M | $334.84M | $209.53M |
| Cost of revenue | $203.42M | $278.22M | $235.46M | $208.36M | $118.64M |
| Gross profit | $131.68M | $186.56M | $184.60M | $126.48M | $90.88M |
| R&D expense | $14.91M | $17.18M | $15.35M | $6.95M | $5.62M |
| SG&A expense | $123.11M | $123.69M | $113.00M | $77.48M | $47.60M |
| Operating income | -$2.24M | $45.85M | $54.18M | $39.87M | $38.38M |
| Interest expense | $28.84M | $26.87M | $23.79M | $17.93M | $21.24M |
| Pretax income | -$57.57M | $11.07M | $19.11M | $14.06M | $10.53M |
| Income tax | $1.27M | $3.78M | -$1.07M | $17.97M | $14.35M |
| Net income | -$55.42M | $4.28M | $18.78M | -$7.20M | -$6.87M |
| EPS (basic) | -0.88 | 0.07 | 0.30 | -0.17 | -0.18 |
| EPS (diluted) | -0.88 | 0.07 | 0.30 | -0.17 | -0.18 |
| Weighted avg. shares (diluted) | 63.23M | 63.49M | 63.19M | 42.30M | 39.22M |
| Balance sheet | |||||
| Cash & equivalents | $32.70M | $44.47M | $48.13M | $33.48M | $36.05M |
| Short-term investments | — | — | $212,703 | $265,123 | $425,976 |
| Receivables | $165.86M | $207.32M | $158.01M | $111.75M | $88.78M |
| Inventory | $87.61M | $125.93M | $140.43M | $126.04M | $61.04M |
| Current assets | $308.31M | $408.67M | $397.11M | $297.71M | $211.49M |
| PP&E, netmay include right-of-use assets (IFRS) | $74.58M | $74.57M | $67.85M | $49.91M | $47.95M |
| Goodwill | $112.16M | $112.16M | $112.16M | $36.07M | $28.75M |
| Intangibles | $181.17M | $176.89M | $173.78M | $76.70M | $67.34M |
| Total assets | $763.65M | $852.55M | $818.06M | $518.22M | $394.59M |
| Current liabilities | $337.99M | $329.31M | $298.71M | $222.67M | $168.04M |
| Short-term debt | $119.73M | $136.75M | $107.64M | $71.30M | $76.79M |
| Long-term debt | $38.20M | $42.10M | $60.67M | $74.18M | $47.99M |
| Total debt | $157.93M | $178.85M | $168.31M | $145.48M | $124.77M |
| Total liabilities | $468.43M | $501.17M | $487.56M | $359.92M | $304.30M |
| Shareholders' equity | $265.44M | $315.04M | $298.59M | $127.36M | $67.74M |
| Net debt | $125.23M | $134.38M | $120.18M | $112.00M | $88.73M |
| Cash flow statement | |||||
| Operating cash flow | $49.91M | $41.72M | $2.59M | -$17.52M | -$6.21M |
| Capital expenditure | $5.64M | $9.79M | $11.36M | $3.46M | $2.81M |
| Free cash flow | $44.26M | $31.93M | -$8.77M | -$20.97M | -$9.01M |
| Investing cash flow | -$6.13M | -$28.73M | -$25.73M | $2.90M | -$8.31M |
| Financing cash flow | -$50.71M | -$10.06M | $32.95M | $14.82M | $7.36M |
| Stock-based compensation | $4.39M | $14.13M | $3.42M | $1.43M | $1.66M |
| Dividends paid | $72,051 | $174,800 | $452,129 | — | — |
| Share buybacks | $926,899 | $734,388 | $3.00M | — | $3.50M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.